Clinical trials
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,720 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04996121RecruitingPhase 1/Phase 2
Drug for tumors with NTRK or ROS1 gene fusions
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05552937RecruitingPhase 2
Tafasitamab plus lenalidomide for relapsed large B-cell lymphoma
This trial studies whether the combination of tafasitamab and lenalidomide can work better and be safe for people whose large B-cell lymphoma has returned or did not respond. It may help by targeting lymphoma cells and supporting immune activity, while monitoring side effects closely.
Hangzhou, ZhejiangAges 18 years+ - NCT05246345Recruiting
Study for chronic lymphocytic leukemia after venetoclax failure
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
AmiensAges 18 years+ - NCT07874100Recruiting
Personalized treatment for acute myeloid leukemia
This study looks for markers in your blood to help doctors choose the most effective treatment, especially a drug called venetoclax. By understanding your leukemia at a very detailed level, they hope to improve outcomes for you and others.
MilanAges 18 years+ - NCT05243212RecruitingPhase 1/Phase 2
CAR-T cell therapy for multiple myeloma
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
Ramat GanAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06277427Recruiting
CAR-T cell therapy for refractory vasculitis and lupus nephritis
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
Wuhan, HubeiAges 18–70 - NCT06232096RecruitingPhase 1/Phase 2
Study of MBS314 for relapsed or refractory multiple myeloma
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
BeijingAges 18 years+ - NCT04243785RecruitingPhase 1
Testing BTX-A51 for hard-to-treat AML or high-risk MDS
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
Duarte, CaliforniaAges 18 years+ - NCT06195800Recruiting
Biomarkers after stem cell transplant for neurological diseases
This trial looks at biomarkers (biological signs in your blood) in people with immune-mediated neurological diseases. It compares those getting a stem cell transplant to those on high-efficacy MS treatments to understand how these therapies work.
Sheffield, EnglandAges 16 years+ - NCT06252298RecruitingPhase 1
Testing a new drug for CD38-positive blood cancers
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06404528Recruiting
Low-dose chemo under low blood sugar for advanced solid tumors
This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.
Wuxi, JiangsuAges 18–75 - NCT06421298RecruitingPhase 2
Tafolecimab and sintilimab plus chemo for advanced lung cancer
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06430502Recruiting
Cancer vaccine plus immunotherapy for advanced solid tumors
This trial tests a cancer vaccine (called TTV) combined with a PD-1 inhibitor (a type of immunotherapy) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this new combination helps shrink tumors or slow cancer growth.
Wuxi, JiangsuAges 18–85 - NCT05310591RecruitingPhase 1/Phase 2
Study anti-PD1 treatment with Kymriah re-dosing for leukemia
This Phase 1/2 trial studies giving an anti-PD1 antibody (like pembrolizumab or nivolumab) along with a second Kymriah (tisagenlecleucel) infusion in children and young adults whose B-cell leukemia is coming back or their Kymriah effect has faded. It may help the new immune treatment work better after the first Kymriah.
BordeauxAges 1–25 - NCT04050345Recruiting
Blood test to spot DNA changes after early colon cancer surgery
This study checks a “cell-free tumor DNA” blood test to see if cancer mutations can predict relapse after surgery for early colorectal cancer. If results look risky, they may help guide closer follow-up and future treatment decisions.
Milton Keynes, BuckinghamshireAges 18 years+ - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT06306456RecruitingPhase 1/Phase 2
GH21 combined with osimertinib for advanced lung cancer
This trial tests a new drug (GH21) combined with the targeted therapy osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to a similar treatment. The goal is to see if the combination can help when the cancer has progressed.
Hefei, AnhuiAges 18 years+ - NCT07800936RecruitingPhase 1
Injecting drug HP007 for advanced solid tumors that stopped responding to treatment
This trial tests an injected drug directly into tumors for people with advanced solid tumors like breast, head and neck, melanoma, prostate, or liver cancer that have not responded to standard treatments. It may help shrink tumors or slow their growth.
Changchun, JilinAges 18–75 - NCT05504772Recruiting
Personalized genetic testing for children with cancer
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
AdelaideAges birth–25 years - NCT06514313RecruitingPhase 2
Study of a drug combo for children with returning soft tissue sarcoma
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
Guangzhou, GuangdongAges 2–21 - NCT07794514Recruiting
Comparing two drugs for liver graft-versus-host disease
This trial compares two medications, belumosudil and ruxolitinib, to see which one works better for a type of graft-versus-host disease (GVHD) that affects the liver after a stem cell transplant. GVHD happens when donor cells attack the patient's body, and this study focuses on patients whose liver GVHD has not improved with steroids or has gotten worse. The study aims to find a more effective treatment to control this condition.
Hangzhou, ZhejiangAges 12 years+ - NCT07793500RecruitingEarly Phase 1
Nebulized drug for lung metastases from solid tumors
This study tests a new drug given as a mist you breathe in, for people whose cancer has spread to the lungs. The goal is to see if it can shrink tumors or slow their growth.
BeijingAges 18–75 - NCT06537843RecruitingPhase 2
Venetoclax, cytarabine and metformin for AML
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
BelémAges 18 years+
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell non-hodgkin lymphoma?
- Yes. Clin2 currently lists 1,720 recruiting relapsed or refractory b-cell non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.